At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 348 target
Drug / intervention
tamsulosin and/or dutasteridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating tamsulosin and/or dutasteride for Prostate Cancer. Completed, enrolled 348 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2005
Enrollment StartNov 2005
Primary CompletionJun 2006
TodayJul 2026
First PostedOct 26, 2005
Enrollment StartNov 1, 2005
Primary CompletionJun 1, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 20.7 years ago
Interventions
tamsulosin and/or dutasteridedrug